Breaking Down Alembic Pharmaceuticals Limited Financial Health: Key Insights for Investors

Dive into a data-driven snapshot of Alembic Pharmaceuticals Limited where top-line momentum and hidden stresses collide: Q2 FY26 revenue from operations jumped to ₹1,910 crore (+16% YoY) driven by a ₹639 crore India Branded Business and a 21% surge in the U.S. Generics segment, while FY25 total income reached ₹6,714.63 crore (up from ₹6,256.93 crore); yet profitability paints a mixed picture with Q2 FY26 PAT at ₹185 crore (+20% YoY) and EBITDA at ₹325 crore (EBITDA margin 17%), contrasted by a decline in gross profit margin to 14.76% in 2025 and interest costs rising to nearly ₹79 crore; balance sheet metrics show total liabilities of ₹7,607 crore and shareholders' funds at ₹5,191 crore in 2025 with a strikingly low debt-to-equity of 0.006 and equity ratio of 93.4%, while liquidity flags emerge-operating cash flow down to ₹87 crore in 2025 and closing cash at ₹83 crore-even as R&D at 10% of Q2 FY26 revenue and the Utility Therapeutics acquisition point to growth levers; read on for a line-by-line breakdown of revenue, margins, cash flows, valuation multiples and risk vectors to inform your investment view

Alembic Pharmaceuticals Limited (APLLTD.NS) - Revenue Analysis

• Q2 FY26 revenue from operations: ₹1,910 crore (+16% YoY).
• India Branded Business (Q2 FY26): ₹639 crore (+5% YoY).
• U.S. Generics (Q2 FY26): revenue growth of 21% YoY, signalling strong international traction.

• India Branded Business: ₹639 crore in Q2 FY26, representing a stable domestic growth engine (+5% YoY).
• U.S. Generics: strongest growth pocket with +21% YoY in Q2 FY26, supporting higher-margin international sales.
• Quarterly trend: Q3 FY25 ₹1,692.74 crore → Q4 FY25 ₹1,783.83 crore → Q2 FY26 ₹1,910 crore, showing sequential and annual improvement.

• Diversified revenue base with meaningful contributions from India branded and U.S. generics reduces single-market concentration risk.
• Consistent quarter-on-quarter growth in FY25 and double-digit YoY in Q2 FY26 suggests operating leverage potential if cost control holds.
• Monitor pipeline and pricing dynamics in U.S. generics and volume trends in India branded for sustainability of growth rates.

Alembic Pharmaceuticals Limited (APLLTD.NS) - Profitability Metrics

• Q2 FY26: Profit After Tax (PAT) of ₹185 crore - up 20% year-over-year.
• Q2 FY26: EBITDA ₹325 crore - up 26% YoY; EBITDA margin 17%.
• Q3 FY25: Quarterly profit fell 23.29% to ₹138.42 crore from ₹180.45 crore YoY.
• FY25 (year ended 31 Mar 2025): Net profit ₹582.01 crore, down from ₹615.82 crore the prior year.
• Gross profit margin trend: 28.77% in 2021 → 14.76% in 2025, indicating sustained margin pressure.
• Interest expense: ₹16 crore in 2021 → nearly ₹79 crore in 2025, a significant increase that compresses net profit.

• Key drivers: Q2 FY26 operational recovery (EBITDA +26%), but underlying margin contraction and higher interest costs remain material headwinds.
• Investor focus: monitor gross margin stabilization, trajectory of finance costs, and sustainability of EBITDA margin improvement in subsequent quarters.
• For broader shareholder context and ownership trends, see: Exploring Alembic Pharmaceuticals Limited Investor Profile: Who's Buying and Why?

Alembic Pharmaceuticals Limited (APLLTD.NS) - Debt vs. Equity Structure

• Total liabilities increased to ₹7,607 crore as of March 31, 2025 (from ₹5,989 crore in 2020), reflecting higher borrowings and current liabilities.
• Long-term borrowings were eliminated by 2025; short-term borrowings rose materially to ₹1,196 crore, indicating a shift toward near-term funding.
• Shareholders' funds rose to ₹5,191 crore in 2025 from ₹3,219 crore in 2020, driven by higher reserves.
• Debt-to-equity ratio stood at 0.006 in 2025 - effectively negligible leverage.
• Equity ratio was 93.4% in 2025, underscoring a capital structure dominated by equity.
• Return on Equity (ROE) was 13.3% in 2025, supported by strong net income; however, part of this ROE may be inflated by non-recurring items.

Alembic Pharmaceuticals Limited (APLLTD.NS) - Liquidity and Solvency

• Operating cash flow sharply peaked at ₹1,463 crore in 2021 and declined to ₹87 crore in 2025, highlighting volatility in core cash generation.
• Closing cash and cash equivalents fell to ₹83 crore in 2025 from ₹120 crore in 2024, a modest deterioration in the net cash position.
• Net cash from financing swung to an inflow of ₹403.61 crore in 2025, reversing prior years' outflows and supporting liquidity.
• Operating cash flow to net income ratio of 0.28 in 2025 signals moderate cash conversion; free cash flow to net income of 0.11 in 2025 points to potential near-term cash constraints despite solid reported earnings.

• Short-term liquidity: reduced closing cash (₹83 crore) and low operating cash in 2025 increase reliance on financing activity (₹403.61 crore inflow) to meet obligations and invest in operations.
• Solvency perspective: episodic strong cash generation (2021) demonstrates capacity to deleverage in favorable years, but multi-year decline to 2025 raises monitoring needs around interest coverage and debt-servicing should operating cash remain constrained.
• Key metrics to watch: trend in operating cash conversion (currently 0.28), free cash flow generation (0.11), working capital movements, and recurrence of financing inflows vs. sustainable operational improvement.

Alembic Pharmaceuticals Limited (APLLTD.NS) - Valuation Analysis

• Operational efficiency: EBITDA margin at 76% indicates exceptional conversion of revenue into cash-operating profit, highlighting cost control and high-margin product mix.
• Core profitability: EBIT margin of 37.4% confirms strong earnings from operations after depreciation and amortization.
• Capital structure and leverage: debt-to-equity of 0.006 and equity ratio 93.4% point to virtually debt-free financing and low interest burden, reducing financial risk.
• Return metrics: ROE of 13.3% is healthy for the sector but may be partially driven by non-recurring items-investors should adjust for one-offs when projecting sustainable returns.
• Net income trend: Net profit fell to ₹582.01 crore in FY2025 from ₹615.82 crore in FY2024, a decline of ₹33.81 crore (-5.5%), which warrants review of exceptional items, tax impacts or product mix shifts.

• Low leverage (D/E 0.006) reduces bankruptcy and interest-rate sensitivity, supporting a lower cost of equity in valuation models.
• High EBITDA margin (76%) justifies premium multiples if margins are sustainable; confirm by analyzing segment margins and product pipeline profitability.
• ROE at 13.3% is attractive, but normalize for non-recurring gains/losses before using as a forecast anchor.
• The slight decline in net profit (-5.5%) calls for a close look at revenue growth, gross margin trends, R&D and selling expenses, and tax/one-off items that affected FY2025 results.

Alembic Pharmaceuticals Limited (APLLTD.NS) - Risk Factors

• Margin compression: Gross profit margin fell from 28.77% in FY2021 to 14.76% in FY2025, reflecting significant margin pressure that could stem from rising input costs, pricing pressure in key markets, product mix shifts, or increased competition.
• Rising finance costs: Interest expense increased from ₹16 crore in FY2021 to ~₹79 crore in FY2025, reducing net profitability and increasing earnings sensitivity to interest rate movements.
• Operating cash flow deterioration: Cash flow from operations declined from ₹1,463 crore in FY2021 to ₹87 crore in FY2025, signaling potential liquidity strain or working-capital intensity.
• Weakened liquidity buffer: Closing cash & cash equivalents fell to ₹83 crore in FY2025 from ₹120 crore in FY2024, tightening short-term cash flexibility.
• Low conversion of profits to free cash flow: Free cash flow to net income ratio stood at 0.11 in FY2025, indicating limited cash generation relative to reported earnings and potential challenges funding capex, dividends, or debt without external financing.
• Declining net profit: Net profit decreased to ₹582.01 crore in FY2025 from ₹615.82 crore in FY2024, underscoring margin and cost pressures already impacting the bottom line.

• Operational risk: Continued margin erosion could force pricing actions, cost-cutting, or portfolio repricing that may impact growth investments.
• Refinancing and interest-rate risk: Elevated interest costs increase vulnerability to further rate hikes and refinancing needs; worsening cash flow heightens refinancing risk.
• Liquidity and working-capital risk: Sharp decline in operating cash flow and lower cash balances point to constrained liquidity, which could limit strategic flexibility or necessitate external funding.
• Profit quality risk: Low free-cash-flow conversion relative to net income raises concerns about earnings quality and the company's ability to sustain capex, dividends, or deleveraging without new financing.

Alembic Pharmaceuticals Limited (APLLTD.NS) - Growth Opportunities

Alembic Pharmaceuticals Limited (APLLTD.NS) shows several concrete growth levers backed by recent financial and strategic moves. Key metrics from Q2 FY26 and FY25 highlight investment in innovation, international expansion and solid operating profitability.

• R&D intensity: R&D expenditure accounted for 10% of revenue in Q2 FY26, underscoring a sustained push to build a differentiated pipeline.
• Strategic M&A: Completed acquisition of Utility Therapeutics in Q2 FY26 to accelerate entry into branded drugs in the U.S. market.
• Product focus: Targeting complex, high-value segments - injectables, peptides, oral solids and drug discovery - which typically command higher margins and barrier-to-entry advantages.
• International growth: U.S. Generics revenue rose 21% in Q2 FY26, signaling robust traction in key developed markets.
• Domestic branded presence: India Branded Business delivered ₹639 crore in Q2 FY26 revenue, up 5% year-on-year, supporting stable cash flows.
• Operational profitability: Reported EBIT margin of 37.4% in 2025, reflecting strong core profitability and operating leverage.

Primary growth channels and considerations:

• Pipeline maturation: Continued R&D at 10% of revenue should translate into higher-value product launches over the medium term.
• U.S. branded play: Utility Therapeutics acquisition enables branded launches and margin capture in the U.S.; execution risk relates to market access and integration.
• Specialty manufacturing: Focus on injectables and peptides positions Alembic to capture complex generics and specialty market premiums.
• India market resilience: ₹639 crore contribution from India Branded Business provides a stable domestic revenue base while international segments scale.
• Margin sustainability: 37.4% EBIT margin in 2025 indicates headroom to fund growth, but margin durability depends on product mix and integration costs.

For additional background on the company's history, ownership and business model, see: Alembic Pharmaceuticals Limited: History, Ownership, Mission, How It Works & Makes Money